Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro by Christian Hammer, Jane Ruppel, Lynn Kamen, Julie Hunkapiller, Ira Mellman, Valerie Quarmby

Connect to this object online.

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2) by Solange Peters, Peter R. Galle, Coen A. Bernaards, Marcus Ballinger, René Bruno, Valerie Quarmby, Jane Ruppel, Alexandr Vilimovskij, Benjamin Wu, Nitzan Sternheim, Martin Reck

Connect to this object online.

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1) by Benjamin Wu, Nitzan Sternheim, Priya Agarwal, Julia Suchomel, Shweta Vadhavkar, Rene Bruno, Marcus Ballinger, Coen A. Bernaards, Phyllis Chan, Jane Ruppel, Jin Jin, Sandhya Girish, Amita Joshi, Valerie Quarmby

Connect to this object online.

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins by Andrzej M. Kierzek, Timothy P. Hickling, Isabel Figueroa, J. Cory Kalvass, Marjoleen Nijsen, Krithika Mohan, Geertruida M. Veldman, Akihiro Yamada, Hiroyuki Sayama, Sachiko Yokoo, Abhishek Gulati, Renu S. Dhanikula, Jochem Gokemeijer, Tarek A. Leil, Craig J. Thalhauser, Mario Giorgi, Maciej J. Swat, Vijayalakshmi Chelliah, Ben G. Small, Neil Benson, Michael Walker, Kapil Gadkar, Valerie Quarmby, Rong Deng, Andrea Ferrante, Gemma L. Dickinson, Jan‐Stefan Van Der Walt, Lian Zhou, Xiaoying Chen, Hannah M. Jones, Jatin Narula, Sophie Tourdot, Thierry Lavé, Benjamin Ribba, Piet H. van derGraaf

Connect to this object online.